IL270623A - - Google Patents
Info
- Publication number
- IL270623A IL270623A IL27062319A IL27062319A IL270623A IL 270623 A IL270623 A IL 270623A IL 27062319 A IL27062319 A IL 27062319A IL 27062319 A IL27062319 A IL 27062319A IL 270623 A IL270623 A IL 270623A
- Authority
- IL
- Israel
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2017062031 | 2017-05-18 | ||
| PCT/EP2018/062862 WO2018210994A1 (en) | 2017-05-18 | 2018-05-17 | Phenyl derivatives as pge2 receptor modulators |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL270623A true IL270623A (enExample) | 2019-12-31 |
| IL270623B IL270623B (en) | 2022-11-01 |
| IL270623B2 IL270623B2 (en) | 2023-03-01 |
Family
ID=62186480
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL270623A IL270623B2 (en) | 2017-05-18 | 2018-05-17 | History of phenyl as pge2 receptor modulators |
Country Status (32)
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CR20180323A (es) | 2015-11-20 | 2018-08-06 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituídos como moduladores de los receptores de pge2 |
| KR102612140B1 (ko) | 2017-05-18 | 2023-12-08 | 이도르시아 파마슈티컬스 리미티드 | 피리미딘 유도체 |
| AR111808A1 (es) | 2017-05-18 | 2019-08-21 | Idorsia Pharmaceuticals Ltd | Derivados de pirimidina como moduladores del receptor de pge2 |
| US11325899B2 (en) | 2017-05-18 | 2022-05-10 | Idorsia Pharmaceuticals Ltd | Benzofurane and benzothiophene derivatives as PGE2 receptor modulators |
| JP2021510153A (ja) | 2018-01-05 | 2021-04-15 | アイカーン スクール オブ メディシン アット マウント サイナイ | 膵臓ベータ細胞の増殖を増加させる方法、治療方法、および組成物 |
| ES3038913T3 (en) | 2018-03-20 | 2025-10-15 | Icahn School Med Mount Sinai | Beta-carboline derivatives as dyrk1a inhibitors for the treatment of e.g. diabetes |
| CA3124353A1 (en) * | 2018-12-31 | 2020-07-09 | Icahn School Of Medicine At Mount Sinai | Kinase inhibitor compounds and compositions and methods of use |
| JP7816164B2 (ja) | 2020-11-13 | 2026-02-18 | 小野薬品工業株式会社 | Ｅｐ４拮抗薬と免疫チェックポイント阻害物質との併用によるがん治療 |
| JP2024524986A (ja) | 2021-06-24 | 2024-07-09 | レザボア ニューロサイエンス，インコーポレイテッド | Ｅｐ２アンタゴニスト化合物 |
| EP4359399A4 (en) | 2021-06-24 | 2025-04-23 | Reservoir Neuroscience, Inc. | EP2 antagonist compounds |
| TW202604507A (zh) | 2024-05-02 | 2026-02-01 | 瑞士商愛杜西亞製藥有限公司 | 經n-取代之吲哚衍生物的結晶形式 |
Family Cites Families (88)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5948786A (en) | 1996-04-12 | 1999-09-07 | Sumitomo Pharmaceuticals Company, Limited | Piperidinylpyrimidine derivatives |
| AU2000234451B2 (en) | 2000-03-24 | 2005-09-29 | Asterand Uk Acquisition Limited | Use of prostanoid ep4 receptor antagonists for the treatment of headache and assays for such antagonists |
| HN2001000224A (es) | 2000-10-19 | 2002-06-13 | Pfizer | Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos. |
| GB0031295D0 (en) | 2000-12-21 | 2001-01-31 | Glaxo Group Ltd | Naphthalene derivatives |
| GB0031302D0 (en) | 2000-12-21 | 2001-01-31 | Glaxo Group Ltd | Napthalene derivatives |
| GB0103269D0 (en) | 2001-02-09 | 2001-03-28 | Glaxo Group Ltd | Napthalene derivatives |
| JP2005532291A (ja) | 2002-04-12 | 2005-10-27 | ファイザー株式会社 | 抗炎症薬および鎮痛薬としてのピラゾール化合物 |
| MXPA04009961A (es) | 2002-04-12 | 2004-12-13 | Pfizer | Compuestos de imidazol como agentes anti-inflamatorios y analgesicos. |
| CA2485485A1 (en) | 2002-05-23 | 2003-12-04 | Theratechnologies Inc. | Antagonistic peptides of prostaglandin e2 receptor subtype ep4 |
| CN100408570C (zh) | 2003-01-29 | 2008-08-06 | 阿斯特兰德英国有限公司 | Ep4受体拮抗剂 |
| CN1871240B (zh) | 2003-08-26 | 2012-11-07 | 帝人制药株式会社 | 吡咯并嘧啶酮衍生物 |
| CA2536870C (en) | 2003-09-03 | 2009-10-27 | Pfizer Inc. | Phenyl or pyridyl amide compounds as prostaglandin e2 antagonists |
| US8084457B2 (en) | 2003-09-15 | 2011-12-27 | Lead Discovery Center Gmbh | Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases |
| GB0324269D0 (en) | 2003-10-16 | 2003-11-19 | Pharmagene Lab Ltd | EP4 receptor antagonists |
| AU2005238291A1 (en) | 2004-05-04 | 2005-11-10 | Pfizer Inc. | Substituted methyl aryl or heteroaryl amide compounds |
| KR20070006890A (ko) | 2004-05-04 | 2007-01-11 | 화이자 인코포레이티드 | 오르토 치환된 아릴 또는 헤테로아릴 아마이드 화합물 |
| HN2005000795A (es) | 2004-10-15 | 2010-08-19 | Aventis Pharma Inc | Pirimidinas como antagonistas del receptor de prostaglandina d2 |
| ATE533766T1 (de) | 2005-05-19 | 2011-12-15 | Merck Canada Inc | Chinolinderivate als ep4-antagonisten |
| WO2006128129A2 (en) | 2005-05-26 | 2006-11-30 | Synta Pharmaceuticals Corp. | Method for treating cancer |
| DOP2007000068A (es) | 2006-04-12 | 2007-10-31 | Sanofi Aventis Us Llc | Compuestos de amino-pirimidina 2,6-sustituidos-4-monosustituidos como antagonistas del receptor de prostaglandina d2 |
| JP5244091B2 (ja) | 2006-04-24 | 2013-07-24 | メルク カナダ インコーポレイテッド | Ｅｐ４受容体アンタゴニストとしてのインドールアミド誘導体 |
| CA2654811A1 (en) | 2006-06-12 | 2007-12-21 | Merck Frosst Canada Ltd. | Indoline amide derivatives as ep4 receptor ligands |
| US20080280891A1 (en) | 2006-06-27 | 2008-11-13 | Locus Pharmaceuticals, Inc. | Anti-cancer agents and uses thereof |
| WO2008008059A1 (en) | 2006-07-12 | 2008-01-17 | Locus Pharmaceuticals, Inc. | Anti-cancer agents ans uses thereof |
| CA2657227A1 (en) | 2006-07-14 | 2008-01-17 | Novartis Ag | Pyrimidine derivatives as alk-5 inhibitors |
| AU2007283404B2 (en) | 2006-08-11 | 2013-04-18 | Merck Canada Inc. | Thiophenecarboxamide derivatives as EP4 receptor ligands |
| WO2008039882A1 (en) | 2006-09-30 | 2008-04-03 | Sanofi-Aventis U.S. Llc | A combination of niacin and a prostaglandin d2 receptor antagonist |
| CA2679175C (en) | 2007-02-26 | 2015-01-13 | Merck Frosst Canada Ltd. | Indole and indoline cyclopropyl amide derivatives as ep4 receptor antagonists |
| CN101636385B (zh) | 2007-03-26 | 2012-09-05 | 默克弗罗斯特加拿大有限公司 | 作为ep4受体拮抗剂的萘和喹啉磺酰脲衍生物 |
| KR20090122931A (ko) | 2007-03-26 | 2009-12-01 | 아스테라스 세이야쿠 가부시키가이샤 | 오르니틴 유도체 |
| EP2014657A1 (de) * | 2007-06-21 | 2009-01-14 | Bayer Schering Pharma Aktiengesellschaft | Diaminopyrimidine als Modulatoren des EP2-Rezeptors |
| EP2172447A4 (en) | 2007-07-03 | 2011-08-24 | Astellas Pharma Inc | amide |
| AU2008309517B2 (en) | 2007-10-12 | 2013-03-14 | Astrazeneca Ab | Inhibitors of protein kinases |
| EP2254415B1 (en) | 2008-02-19 | 2013-01-23 | Janssen Pharmaceutica, N.V. | Aryl-hydroxyethylamino-pyrimidines and triazines as modulators of fatty acid amide hydrolase |
| ES2518919T3 (es) | 2008-05-14 | 2014-11-05 | Astellas Pharma Inc. | Derivados del ácido 4-(Indol-7-ilcarbonilaminometil)ciclohexanocarboxílico como antagonistas del receptor EP4 útiles para el tratamiento de la insuficiencia renal crónica o la nefropatía diabética |
| US20130225528A1 (en) | 2008-05-21 | 2013-08-29 | Ariad Pharmaceuticals, Inc. | Phosphorus Derivatives as Kinase Inhibitors |
| CN102149384B (zh) | 2008-08-14 | 2014-08-20 | 南京奥昭生物科技有限公司 | 作为ep4受体拮抗剂的杂环酰胺衍生物 |
| CN102164942B (zh) | 2008-09-19 | 2017-02-15 | 生物科技研究有限公司 | 三萜系化合物及其使用的方法 |
| MX2011003166A (es) | 2008-09-25 | 2011-04-27 | Merck Frosst Canada Ltd | Derivados de sulfonilurea beta-carbolina como antagonistas del receptor ep4. |
| WO2011022348A1 (en) | 2009-08-18 | 2011-02-24 | Janssen Pharmaceutica Nv | Ethylene diamine modulators of fatty acid amide hydrolase |
| CN102711757A (zh) | 2009-11-23 | 2012-10-03 | 莱西肯医药有限公司 | 用于治疗肠易激综合征的方法和分析法 |
| BR112012029647A2 (pt) | 2010-05-21 | 2016-08-02 | Chemilia Ab | novos derivados de pirimidinas |
| WO2012039972A1 (en) | 2010-09-21 | 2012-03-29 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition |
| ES2537017T3 (es) | 2010-09-29 | 2015-06-01 | Nb Health Laboratory Co. Ltd. | Anticuerpo dirigido contra el receptor EP4 de la prostaglandina E2 humano |
| WO2012066065A1 (en) | 2010-11-17 | 2012-05-24 | Novartis Ag | Phenyl-heteroaryl amine compounds and their uses |
| CA2816679A1 (en) | 2010-11-17 | 2012-05-24 | Novartis Ag | 3-(aminoaryl)-pyridine compounds |
| WO2012076063A1 (en) | 2010-12-10 | 2012-06-14 | Rottapharm S.P.A. | Pyridine amide derivatives as ep4 receptor antagonists |
| WO2012103071A2 (en) | 2011-01-25 | 2012-08-02 | Eisai R&D Management Co., Ltd. | Compounds and compositions |
| MX2013010898A (es) | 2011-03-24 | 2013-12-06 | Chemilia Ab | Novedoso derivados de la pirimidina. |
| WO2012149528A1 (en) | 2011-04-29 | 2012-11-01 | Exelixis, Inc. | Inhibitors of inducible form of 6-phosphofructose-2-kinase |
| EP2721011B1 (en) | 2011-06-20 | 2017-09-06 | Emory University | Prostaglandin receptor ep2 antagonists, derivatives, compositions, and uses related thereto |
| PL2729445T3 (pl) | 2011-07-04 | 2016-04-29 | Rottapharm Biotech Srl | Cykliczne pochodne aminowe jako antagoniści receptora EP4 |
| EP2554662A1 (en) | 2011-08-05 | 2013-02-06 | M Maria Pia Cosma | Methods of treatment of retinal degeneration diseases |
| WO2013090552A1 (en) | 2011-12-13 | 2013-06-20 | Yale University | Compositions and methods for reducing ctl exhaustion |
| SG11201406584TA (en) | 2012-04-24 | 2014-11-27 | Vertex Pharma | Dna-pk inhibitors |
| AR091429A1 (es) | 2012-06-29 | 2015-02-04 | Lilly Co Eli | Compuestos de fenoxietil piperidina |
| TWI572597B (zh) | 2012-06-29 | 2017-03-01 | 美國禮來大藥廠 | 二甲基－苯甲酸化合物 |
| EP2711364A1 (en) | 2012-09-21 | 2014-03-26 | Chemilia AB | 4-(Indolyl or benzimidazolyl)amino-2-(2-(indol-3-yl)ethyl)aminopyrimidines useful for the treatment of cancer |
| PE20151412A1 (es) | 2012-11-27 | 2015-10-10 | Thomas Helledays Stiftelse For Medicinsk Forskning | Derivados de pirimidin-2,4-diamina para el tratamiento de cancer |
| UA115576C2 (uk) | 2012-12-06 | 2017-11-27 | Байєр Фарма Акцієнгезелльшафт | Похідні бензимідазолу як антагоністи ер4 |
| EP2765128A1 (en) | 2013-02-07 | 2014-08-13 | Almirall, S.A. | Substituted benzamides with activity towards EP4 receptors |
| TW201443004A (zh) | 2013-02-15 | 2014-11-16 | Lilly Co Eli | 苯氧基乙氧基化合物 |
| TWI636046B (zh) | 2013-05-17 | 2018-09-21 | 美國禮來大藥廠 | 苯氧基乙基二氫－１ｈ－異喹啉化合物 |
| BR112015030095B1 (pt) | 2013-05-30 | 2023-02-28 | Idorsia Pharmaceuticals Ltd | Moduladores do receptor de cxcr7 |
| CN105431416B (zh) | 2013-06-12 | 2019-01-08 | 科研制药株式会社 | 4-炔基咪唑衍生物和含有其作为有效成分的药物 |
| MX2016002544A (es) | 2013-09-04 | 2016-06-17 | Squibb Bristol Myers Co | Compuestos utiles como inmunomoduladores. |
| RS57508B1 (sr) | 2013-09-06 | 2018-10-31 | Aurigene Discovery Tech Ltd | 1,2,4-derivati oksadiazola kao imunomodulatori |
| WO2015044900A1 (en) | 2013-09-27 | 2015-04-02 | Aurigene Discovery Technologies Limited | Therapeutic immunomodulating compounds |
| KR102411227B1 (ko) | 2013-10-17 | 2022-06-21 | 버텍스 파마슈티칼스 인코포레이티드 | Dna-pk 억제제로서 (s)-n-메틸-8-(1-((2'-메틸-[4,5'-비피리미딘]-6-일)아미노)프로판-2-일)퀴놀린-4-카복스아미드 및 이의 듀테로화된 유도체의 공결정 |
| SI3057959T1 (en) * | 2013-10-17 | 2018-07-31 | Vertex Pharmaceuticals Incorporated | DNA-PK INHIBITORS |
| JP6200596B2 (ja) | 2013-12-17 | 2017-09-20 | イーライ リリー アンド カンパニー | ジメチル安息香酸化合物 |
| HUE035698T2 (en) | 2013-12-17 | 2018-05-28 | Lilly Co Eli | Phenoxyethyl ring amine derivatives and their activity as EP4 receptor modulator |
| TW201607943A (zh) | 2013-12-19 | 2016-03-01 | 拜耳製藥公司 | 作為ｅｐ４配體之新穎苯并咪唑衍生物 |
| TW201623277A (zh) | 2014-03-26 | 2016-07-01 | 安斯泰來製藥股份有限公司 | 醯胺化合物 |
| WO2015167825A1 (en) | 2014-04-29 | 2015-11-05 | Emory University | Prostaglandin receptor ep2 antagonists, derivatives, compositions, and uses related thereto |
| SG11201609770TA (en) | 2014-05-23 | 2016-12-29 | Eisai R&D Man Co Ltd | Combination therapies for the treatment of cancer |
| CN106794181A (zh) | 2014-06-04 | 2017-05-31 | 托马斯·黑勒戴药物研究基金会 | 用于治疗炎性和自身免疫性病况的mth1抑制剂 |
| CA2949793C (en) | 2014-06-19 | 2024-02-27 | Ariad Pharmaceuticals, Inc. | Heteroaryl compounds for kinase inhibition |
| WO2016021742A1 (en) | 2014-08-07 | 2016-02-11 | Takeda Pharmaceutical Company Limited | Heterocyclic compounds as ep4 receptor antagonists |
| HUE052969T2 (hu) | 2015-01-09 | 2021-05-28 | Ono Pharmaceutical Co | Triciklusos spiro vegyület |
| JP6689297B2 (ja) | 2015-07-23 | 2020-04-28 | 武田薬品工業株式会社 | 複素環化合物 |
| CA3002144C (en) | 2015-10-16 | 2024-01-23 | Eisai R&D Management Co., Ltd. | Ep4 antagonists |
| CR20180323A (es) | 2015-11-20 | 2018-08-06 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituídos como moduladores de los receptores de pge2 |
| WO2018013840A1 (en) | 2016-07-13 | 2018-01-18 | Vertex Pharmaceuticals Incorporated | Methods, compositions and kits for increasing genome editing efficiency |
| US11325899B2 (en) | 2017-05-18 | 2022-05-10 | Idorsia Pharmaceuticals Ltd | Benzofurane and benzothiophene derivatives as PGE2 receptor modulators |
| AR111808A1 (es) | 2017-05-18 | 2019-08-21 | Idorsia Pharmaceuticals Ltd | Derivados de pirimidina como moduladores del receptor de pge2 |
| PE20191787A1 (es) | 2017-05-18 | 2019-12-24 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituidos |
| KR102612140B1 (ko) | 2017-05-18 | 2023-12-08 | 이도르시아 파마슈티컬스 리미티드 | 피리미딘 유도체 |
-
2018
- 2018-05-17 EA EA201992676A patent/EA201992676A1/ru unknown
- 2018-05-17 MX MX2019013718A patent/MX388256B/es unknown
- 2018-05-17 CN CN201880031321.4A patent/CN110612296A/zh active Pending
- 2018-05-17 KR KR1020197037298A patent/KR102632028B1/ko active Active
- 2018-05-17 CR CR20190559A patent/CR20190559A/es unknown
- 2018-05-17 BR BR112019024109-4A patent/BR112019024109A2/pt not_active IP Right Cessation
- 2018-05-17 UA UAA201911975A patent/UA125123C2/uk unknown
- 2018-05-17 PT PT18725222T patent/PT3625222T/pt unknown
- 2018-05-17 PL PL18725222T patent/PL3625222T3/pl unknown
- 2018-05-17 US US16/614,594 patent/US11712438B2/en active Active
- 2018-05-17 PE PE2019002396A patent/PE20191814A1/es unknown
- 2018-05-17 EP EP18725222.6A patent/EP3625222B1/en active Active
- 2018-05-17 AU AU2018269666A patent/AU2018269666B2/en not_active Ceased
- 2018-05-17 HR HRP20211533TT patent/HRP20211533T1/hr unknown
- 2018-05-17 SG SG11201908729U patent/SG11201908729UA/en unknown
- 2018-05-17 TW TW107116759A patent/TWI765041B/zh not_active IP Right Cessation
- 2018-05-17 ES ES18725222T patent/ES2893452T3/es active Active
- 2018-05-17 AR ARP180101315A patent/AR111941A1/es not_active Application Discontinuation
- 2018-05-17 JP JP2019563491A patent/JP7159214B2/ja not_active Expired - Fee Related
- 2018-05-17 RS RS20211256A patent/RS62440B1/sr unknown
- 2018-05-17 CA CA3060597A patent/CA3060597A1/en active Pending
- 2018-05-17 MA MA49126A patent/MA49126B1/fr unknown
- 2018-05-17 IL IL270623A patent/IL270623B2/en unknown
- 2018-05-17 LT LTEPPCT/EP2018/062862T patent/LT3625222T/lt unknown
- 2018-05-17 DK DK18725222.6T patent/DK3625222T3/da active
- 2018-05-17 SI SI201830422T patent/SI3625222T1/sl unknown
- 2018-05-17 WO PCT/EP2018/062862 patent/WO2018210994A1/en not_active Ceased
- 2018-05-17 HU HUE18725222A patent/HUE056080T2/hu unknown
-
2019
- 2019-09-27 CO CONC2019/0010578A patent/CO2019010578A2/es unknown
- 2019-11-15 PH PH12019502563A patent/PH12019502563A1/en unknown
- 2019-11-15 CL CL2019003275A patent/CL2019003275A1/es unknown
-
2021
- 2021-10-19 CY CY20211100906T patent/CY1124608T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR122021000189A2 (enExample) | ||
| BR112019008823A2 (enExample) | ||
| BR112020006084A8 (enExample) | ||
| BR112019025875B1 (pt) | Sistema de cilindro com estrutura de ocupação de movimento relativo | |
| BR112020011860B1 (pt) | Dispositivo cirúrgico para cortar uma lente dentro de um saco capsular de um olho | |
| BR112020006283B1 (pt) | Placa refinadora, e, refinador para tratamento mecânico de material orgânico/celulósico | |
| BR112020008714B1 (pt) | Uso de medicamentos serotoninérgicos para tratar trombocitopenia induzida por vírus | |
| BR112020006992B1 (pt) | Dispositivo de recolhimento e método para o recolhimento de uma embarcação | |
| BR122022025541B1 (pt) | Dispositivo de acesso iv | |
| BR112019023976B1 (pt) | Sistema e método para comunicar dados de saúde em um ambiente de cuidados de saúde | |
| BR112020003314B1 (pt) | Sistema terapêutico transdérmico para administração transdérmica de um agente ativo, seu método de fabricação, usos de emulsificante, e método para estabilizar uma mistura de revestimento bifásica | |
| BR112020003112B1 (pt) | Método de garantir a viabilidade de uma máquina para uma tarefa agendada | |
| BR112020002577B1 (pt) | Método de melhoria de rendimento de centrifugação dupla para purificação de óleo nutritivo | |
| BR112019016885B1 (pt) | Remodelagem de imagem integrada e codificação de vídeo | |
| BR112020001354B1 (pt) | Método, em uma primeira estação base, para suportar posicionamento de um dispositivo móvel e primeira estação base para suportar posicionamento de um dispositivo móvel | |
| BR112019027876B1 (pt) | Método de codificação para uma comunicação sem fio, codificador, método de decodificação, decodificador, aparelho de comunicação, meio de armazenagem legível por computador, e sistema de comunicações | |
| BR112019026818B1 (pt) | Método de codificação, método de decodificação, aparelho, aparelho de comunicações, terminal, estação base e mídia legível por computador | |
| BR102018011961B1 (pt) | Sistemas, métodos e meio não transitório legível por computador para analisar cores a partir de uma plataforma de mídia social | |
| BR112019026880B1 (pt) | Método de comunicação, método para receber dados, e, dispositivo | |
| BR112019023944B1 (pt) | Combinação farmacêutica para o tratamento de um câncer | |
| BR112019021396B1 (pt) | Processo para fabricação de pululano | |
| BR102018003507B1 (pt) | Sistema de isolamento de tensão de tambor de guincho | |
| BR112019016182B1 (pt) | Método para diagnosticar risco de revisão relacionado a implante | |
| BR112019014127B1 (pt) | Composição farmacêutica para tratamento de tumores | |
| BR112019017156B1 (pt) | Dispositivo, sistema e método de gerenciamento de recepção de pedido, e, meio de armazenamento legível por computador |